ARK Invest's position in GENB, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 1,689,247 | $21.2M | 1.08% | #28 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-26 | ARKG | Buy | Added | 304,851 | $4.9M |
| 2026-07-10 | ARKG | Buy | Added | 54,804 | $785K |
| 2026-07-09 | ARKG | Buy | Added | 57,462 | $903K |
| 2026-07-08 | ARKG | Buy | Added | 61,750 | $980K |
| 2026-07-07 | ARKG | Buy | Added | 44,170 | $716K |
| 2026-07-06 | ARKG | Buy | Added | 92,202 | $1.6M |
| 2026-07-02 | ARKG | Buy | Added | 26,483 | $461K |
| 2026-07-01 | ARKG | Buy | Added | 69,680 | $1.1M |
| 2026-06-30 | ARKG | Buy | Added | 27,949 | $472K |
| 2026-06-29 | ARKG | Buy | Added | 136,406 | $2.3M |
| 2026-06-26 | ARKG | Buy | Added | 63,768 | $1.1M |
| 2026-06-25 | ARKG | Buy | Added | 31,159 | $512K |
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed…
See GENB's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open GENB on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.